Basilea to receive $37.5 million milestone payment on strong Cresemba sales in Europe
Strong European sales of the antifungal drug Cresemba have triggered a $37.5 million milestone payment to Basilea Pharmaceutica.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Reuters, strong sales of Cresemba (isavuconazole) in Europe triggered a milestone payment of USD 37.5 million to Basilea Pharmaceutica.
The payment is tied to the drug's commercial performance in the European market rather than to a separate event at the company itself.
why it matters
Milestone payments of this kind depend directly on product sales and usually matter most for the reporting of a small pharmaceutical company. For investors, the signal concerns Cresemba's momentum in Europe rather than the broader market.
tags
instruments
sources
- Basilea Pharmaceutica - Strong Cresemba Sales In Europe Trigger USD 37.5 Mln Milestone Payment — Reuters, 3 November 2026 at 06:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗